5 Results for "

hnNOS

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "hnNOS" in MCE Product Catalog:

Cat. No.: HY-138564
CAS No.: 165383-72-2
Purity:  98.18%
Target:  

NO Synthase

Research Areas:  

Inflammation/Immunology

NOS-IN-1 is a potent and orally active NO synthase (NOS) isoforms inhibitor with IC50s of 0.1 μM, 1.1 μM, and 0.2 μM for human iNOS (hiNOS), heNOS and hnNOS, respectively .
loading...
    loading...
Cat. No.: HY-149339
CAS No.: 2700326-00-5
Target:  

NO Synthase

Research Areas:  

Neurological Disease

hnNOS-IN-2 (compound 17) is a human neuronal nitric oxide synthase (hnNOS) inhibitor with good metabolic stability. hnNOS-IN-2 can be used for research in neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-W484263
CAS No.: 163490-78-6
Target:  

NO Synthase

Research Areas:  

Neurological Disease

hnNOS-IN-3 (compound 39) is a selective nNOS inhibitor, with a Ki of 0.32 μM. The nNOS binding of hnNOS-IN-3 is competitive with L-arginine. The selectivity of hnNOS-IN-3 for nNOS versus iNOS (Ki=37 μM) and eNOS (Ki=9.4 μM) is 115-fold and 29-fold, respectively .
loading...
    loading...
Cat. No.: HY-181642
Target:  

NO Synthase

Research Areas:  

Neurological Disease Cancer

nNOS-IN-3 (compound 4) is an orally active, selective, neuronal nitric oxide synthase (nNOS) inhibitor with a human hnNOS Ki of 25 nM, rat rnNOS Ki of 18 nM, human heNOS Ki of 58140 nM, human hiNOS Ki of 6422 nM. nNOS-IN-3 binds to nNOS active sites via hydrogen bonds with Glu and chalcogen bonds with Met, fails to form chalcogen bonds with heNOS, and undergoes passive transcellular transport with minimal efflux liability. nNOS-IN-3 can be used for the research of neurodegenerative diseases and melanoma .
loading...
    loading...
Cat. No.: HY-181711
Target:  

NO Synthase

Research Areas:  

Neurological Disease Cancer

nNOS-IN-6 is a human neuronal nitric oxide synthase (hnNOS) inhibitor with a human hnNOS Ki of 16 nM, ~1800-fold selectivity over human eNOS, ~2900-fold selectivity over human iNOS, and a rat nNOS Ki of 34 nM.nNOS-IN-6 exhibits high effective permeability in PAMPA-BBB assays, crosses the blood-brain barrier, and shows sustained systemic exposure, low clearance, and robust brain penetration in mouse in vivo pharmacokinetic studies.nNOS-IN-6 can be used for the research of neurodegenerative diseases, melanoma .
loading...
    loading...